Department of Sociology, Pennsylvania State University, University Park, USA.
Department of Epidemiology, University of Washington, Seattle, Washington, USA.
Harm Reduct J. 2023 Mar 9;20(1):31. doi: 10.1186/s12954-023-00756-3.
During COVID-19, the Substance Abuse and Mental Health Services Administration (SAMHSA) allowed Methadone Maintenance Treatment (MMT) programs to relax in-person MMT requirements to reduce COVID-19 exposure. This study examines patient-reported changes to in-person methadone clinic attendance requirements during COVID-19.
From June 7, 2020, to July 15, 2020, a convenience sample of methadone patients (N = 392) were recruited in collaboration with National Survivors Union (NSU) in 43 states and Washington D.C. through social media (Facebook, Reddit, Twitter, and Web site pop-ups). The community-driven research (CDR) online survey collected information on how patient take-home methadone dosing and in-person drug testing, counseling, and clinic visit frequency changed prior to COVID-19 (before March 2020) to during COVID-19 (June and July 2020).
During the study time period, the percentage of respondents receiving at least 14 days of take-home doses increased from 22 to 53%, while the percentage receiving one or no take-home doses decreased from 22.4% before COVID-19 to 10.2% during COVID-19. In-person counseling attendance decreased from 82.9% to 19.4%. While only 3.3% of respondents accessed counseling through telehealth before COVID-19, this percentage increased to 61.7% during COVID-19. Many respondents (41.3%) reported visiting their clinics in person once a week or more during COVID-19.
During the first wave of COVID-19, methadone patients report decreased in-person clinic attendance and increased take-home doses and use of telehealth for counseling services. However, respondents reported considerable variations, and many were still required to make frequent in-person clinic visits, which put patients at risk of COVID-19 exposure. Relaxations of MMT in-person requirements during COVID-19 should be consistently implemented and made permanent, and patient experiences of these changes should be explored further.
在 COVID-19 期间,物质滥用和心理健康服务管理局(SAMHSA)允许美沙酮维持治疗(MMT)项目放宽对面对面 MMT 的要求,以减少 COVID-19 的暴露。本研究检查了 COVID-19 期间患者对面对面美沙酮诊所就诊要求的报告变化。
从 2020 年 6 月 7 日至 2020 年 7 月 15 日,通过与全国幸存者联盟(NSU)合作,在 43 个州和华盛顿特区,通过社交媒体(Facebook、Reddit、Twitter 和网站弹出窗口)从便利样本中招募了 392 名美沙酮患者。社区驱动的研究(CDR)在线调查收集了关于患者在 COVID-19 之前(2020 年 3 月之前)和 COVID-19 期间(2020 年 6 月和 7 月)美沙酮带回家的剂量和现场药物测试、咨询和诊所就诊频率如何变化的信息。
在研究期间,接受至少 14 天带回家剂量的受访者比例从 22%增加到 53%,而接受一次或没有带回家剂量的受访者比例从 COVID-19 之前的 22.4%下降到 COVID-19 期间的 10.2%。面对面咨询出勤率从 82.9%下降到 19.4%。虽然在 COVID-19 之前只有 3.3%的受访者通过远程医疗获得咨询服务,但这一比例在 COVID-19 期间增加到 61.7%。许多受访者(41.3%)报告在 COVID-19 期间每周或更频繁地亲自到诊所就诊。
在 COVID-19 的第一波疫情中,美沙酮患者报告说,他们减少了到诊所就诊的次数,增加了带回家的剂量,并更多地使用远程医疗进行咨询服务。然而,受访者报告了相当大的差异,许多人仍然需要频繁地亲自到诊所就诊,这使患者面临 COVID-19 暴露的风险。在 COVID-19 期间,应持续实施并永久放宽 MMT 的面对面要求,并进一步探讨患者对这些变化的体验。